文献速递神经肿瘤

世界卫生组织二级脊索样脑膜瘤与透明细胞脑膜瘤的预后因素、生存及治疗

Prognostic Factors, Survival, and Treatment for Intracranial World Health Organization Grade II Chordoid Meningiomas and Clear-Cell Meningiomas.
PubMed 文献 · World Neurosurg · 2018-05-30

回顾性分析2011年1月至2015年12月111例世界卫生组织二级脑膜瘤(脊索样脑膜瘤55例、透明细胞脑膜瘤56例)的临床资料,平均随访45.3个月。脊索样脑膜瘤组8例(14.5%)复发、2例(3.6%)死亡;透明细胞脑膜瘤组22例(39.3%)复发、9例(16.1%)死亡。脊索样脑膜瘤组全切除与良好无进展生存相关(风险比0.144;95%置信区间0.029-0.714;P=0.018);透明细胞脑膜瘤组术前卡氏功能状态评分<80、肿瘤大小≥5 cm、肿瘤大小(每厘米增加)、骨侵犯、手术史及次全切除与较差无进展生存相关。

要点

  • 脊索样脑膜瘤组全切除与良好无进展生存相关(风险比0.144;95%置信区间0.029-0.714;P=0.018)。
  • 透明细胞脑膜瘤组术前卡氏功能状态评分<80、肿瘤大小≥5 cm、骨侵犯、手术史及次全切除与较差无进展生存相关。
  • 透明细胞脑膜瘤组男性、肿瘤大小(每厘米增加)、骨侵犯及手术史与较差总生存相关。

核心结论

  • 本研究显示二级脑膜瘤应实现全切除,肿瘤较大和/或有手术史的患者结局更差。

研究设计与样本

  • 回顾性分析2011年1月至2015年12月111例世界卫生组织二级脑膜瘤的临床资料,其中脊索样脑膜瘤55例、透明细胞脑膜瘤56例,平均随访45.3个月。

主要发现

  • 脊索样脑膜瘤组8例(14.5%)复发、2例(3.6%)死亡;透明细胞脑膜瘤组22例(39.3%)复发、9例(16.1%)死亡。
  • 脊索样脑膜瘤组与透明细胞脑膜瘤组在肿瘤大小(P=0.019)、手术史(P=0.038)及瘤周水肿(P=0.004)方面差异有统计学意义。
  • 脊索样脑膜瘤组全切除与良好无进展生存相关(风险比0.144;95%置信区间0.029-0.714;P=0.018)。
  • 透明细胞脑膜瘤组单因素分析显示术前卡氏功能状态评分<80(P<0.001)、肿瘤大小≥5 cm(P=0.015)、肿瘤大小(每厘米增加)(P=0.022)、骨侵犯(P=0.004)、手术史(P<0.001)及次全切除(P=0.009)与较差无进展生存相关。
  • 透明细胞脑膜瘤组男性(P=0.039)、肿瘤大小(每厘米增加)(P=0.043)、骨侵犯(P=0.030)及手术史(P=0.007)与较差总生存相关。

临床怎么用

  • 作者认为二级脑膜瘤应实现全切除,肿瘤较大和/或有手术史的患者结局更差。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Chordoid meningioma (CM) and clear-cell meningioma (CCM) are rare World Health Organization grade II meningioma subtypes. This study aimed to evaluate favorable factors and appropriate therapeutic strategies for these lesions. METHODS: We retrospectively reviewed clinical data from 111 cases of grade II meningiomas, including 55 cases of CM and 56 cases of CCM, between January 2011 and December 2015. RESULTS: The mean follow-up time of the rare World Health Organization grade II meningiomas (n = 111) was 45.3 months. In the CM group, 8 patients (14.5%) experienced recurrence, and 2 patients (3.6%) died. In the CCM group, 22 patients (39.3%) experienced recurrence, and 9 patients (16.1%) died. Significant differences were observed between the CM and CCM groups in tumor size (P = 0.019), history of surgery (P = 0.038), and peritumoral edema (P = 0.004). In the CM group, gross total resection was associated with favorable progression-free survival (hazard ratio, 0.144; 95% confidence interval, 0.029-0.714; P = 0.018). In the CCM group, univariate analyses showed that preoperative Karnofsky Performance Status <80 (P < 0.001), tumor size ≥5 cm (P = 0.015), tumor size (per-centimeter increase) (P = 0.022), bone invasion (P = 0.004), a history of surgery (P < 0.001), and subtotal resection (P = 0.009) were associated with worse progression-free survival. Male gender (P = 0.039), tumor size (per-centimeter increase) (P = 0.043), bone invasion (P = 0.030), and a history of surgery (P = 0.007) were associated with poor overall survival. CONCLUSIONS: This study showed that gross total resection should be achieved in grade II meningiomas. Patients with larger tumors and/or surgical histories had worse outcomes.

来源:World Neurosurg,查看原文。版权归原作者所有。

引用

  1. Zhang GJ, Zhang YS, Zhang GB, et al. Prognostic Factors, Survival, and Treatment for Intracranial World Health Organization Grade II Chordoid Meningiomas and Clear-Cell Meningiomas. World Neurosurg. 2018. PMID: 29859361. doi:10.1016/j.wneu.2018.04.226

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。